Home » pain

pain

Aug 29, 2017

Prescient Medicine Launches Addiction Risk Test Developed With AutoGenomics

Premium

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

Jul 18, 2016

Proove Biosciences Building Opioid PGx Test Evidence; Experts Question Available Data

Premium

The firm has yet to publish peer-reviewed clinical evaluations, and genetics experts have raised doubts about its choice of targets to predict addiction. 

May 06, 2016

Proove Biosciences Acquires Algynomics

The companies plan to combine their platforms and research to launch new clinical assays and develop procedures and therapeutics to treat pain.

Dec 10, 2015

This Week in Nature

In Nature this week: short tandem repeats contribute to gene expression variation in humans, mutation linked to cold-aggravated peripheral pain, and more.

May 29, 2015

Box Jellyfish Transcriptome, Venom Proteome Reveal Sting Mechanics, Could Inform New Treatments

Premium

The effort has provided a comprehensive view of the toxin proteins involved in the sting of these dangerous jellyfish, which is now being used to identify targets for inhibitory drugs.

May 26, 2015

Family Sequencing Study Reveals Ties Between Pain Perception, Histone Regulatory Gene

Homozygous recessive mutations in the gene PRDM12 appear to contribute to congenital insensitivity to pain by interfering with sensory nerve development.

Dec 22, 2014

Proove Bio Inks Exclusive Licensing Deal with UNC for Pain Dx

The partners will work together to commercialize findings about the genetic basis of pain sensitivity and individual response to commonly prescribed pain medicines.

Sep 26, 2013

McGill Lands $9.7M for Pain Genetics Chair, Lures US Scientist

NEW YORK (GenomeWeb News) – Canada's government has awarded C$10 million (US$9.7 million) to fund a research program at McGill University focused on pain genetics that will be headed by Luda Diatchenko, McGill said yesterday.

Oct 18, 2012

Benitec Provides Pipeline Update Following Tacere Acquisition

Premium

Australian expressed RNAi drug developer Benitec this week provided an update to its pipeline, disclosing that it once again expects to have a candidate in phase I testing next year following its recent acquisition of Tacere Therapeutics.

Jun 21, 2012

Benitec Reveals Delays in its Pipeline Programs as Corporate Revitalization Continues

Premium

Expressed RNAi drug developer Benitec Biopharma this week provided an update on its pipeline, stating that its two lead programs in cancer-associated neuropathic pain and drug-resistant lung cancer have fallen behind schedule as the company further optimizes its therapeutic candi

Pages

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.